RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Summit, November 14-15, 2022

32 slides from RespireRx Pharmaceuticals's conference presentation, Nov 10, 2022

  1. Slide 1: RespireRx Pharmaceuticals Investor Summit, November 14-15, 2022

    Slide 1: RespireRx Pharmaceuticals Investor Summit, November 14-15, 2022

    RespireRx Pharmaceuticals Inc UCL RSH) CH INWESTOR SULIT November 14-15, 2022

  2. Slide 2: Cautionary Notes: Forward Looking Statements

    Slide 2: Cautionary Notes: Forward Looking Statements

    CAUTIONARY NOTES WR RespireRx Pharmaceuticals Inc FORWARD LOOKING STATEMENTS This presentation contains certain forward-looking statements within the meoning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchonge Act of 1934, 0s ame

  3. Slide 3: Cautionary Notes (cont'd): Not a Securities Offering

    Slide 3: Cautionary Notes (cont'd): Not a Securities Offering

    TIONARY NOTES (cont’d) WR RespireRx Pharmaceuticals Inc NOT A SECURITIES OFFERING This presentation is being provided for informational purposes only. This presentation does not constitute an offer to sell, a solicitation of an offer to buy, oa recommendation of any security or any other product or

  4. Slide 4: Neurotransmission

    Slide 4: Neurotransmission

    RespireRx ig Sci G®)Resp pireRx Pharmaceuticals Inc Neurotransmission * Neurons communicate through a process of neurotransmission in which they release chemical neurotransmitters that bind to specific receptors on adjacent neurons. * RespireRx is developing breakthrough drugs to modify neurotransmi

  5. Slide 5: Different Approaches Create Different Platforms

    Slide 5: Different Approaches Create Different Platforms

    Different Approaches Create Different Platforms A RespireRx Pharmaceuticals Inc Directly Acting Agonists/Antagonists * Act directly at the neurotransmitter binding site to either stimulate (agonist) or interfere (antagonist) with the neurotransmitter receptor. * Cannabinoids, such as A9-THC, are dir

  6. Slide 6: Product Candidate Portfolio Summary

    Slide 6: Product Candidate Portfolio Summary

    Product Candidate Portfolio Summary | ResolutionRx | Pharmaceutical Cannabinoids Dronabinol (A9-THC) Treatment of Obstructive Sleep Apnea (OSA) No approved drugs available for OSA Potential multi-billion $ market — estimated 30 million US patients Successful Phase 2B; Phase 3 ready, pending completi

  7. Slide 7: Sleep Apnea: A National Health Epidemic

    Slide 7: Sleep Apnea: A National Health Epidemic

    Sleep Apnea: A National Health Epidemic GQ RespireRx 3 Types of Sleep Apnea * Obstructive (OSA) - a peripheral phenomenon that occurs when throat muscles intermittently relax and block airway during sleep = May be accompanied by snoring * Central (CSA) — a brain-mediated phenomenon that occurs when

  8. Slide 8: Two Successful Phase 2 Trials

    Slide 8: Two Successful Phase 2 Trials

    Two Successful Phase 2 Trials oN) RespireRx nespire’ Inc The Published Literature Can be used to Support a 505(b)2 NDA for Dronabinol in OSA ** p<.02, compared to placebo for Phase 2A Two Phase 2 Trials Have Shown that Dronabinol Treatment Results ina Statistically Significant, Dose Related Improvem

  9. Slide 9: New Formulations Based on Clinical Data

    Slide 9: New Formulations Based on Clinical Data

    AAHI versus Baseline New Formulations Based on Clinical Data Change in AHI in the 1s 4 hours vs. the 2" 4 hours of the night n=17 n= 13 n=8 The plasma half-life of dronabinol is 2 - 4 hours 4st Half = 2nd Half WR RespireRx pespiren Inc Low dose dronabinol is as effective as the high dose in the firs

  10. Slide 10: Present Dronabinol Gel-cap Formulations

    Slide 10: Present Dronabinol Gel-cap Formulations

    Present Dronabinol Gel-cap Formulations RespireRx Pharmaceuticals Inc * Poor and erratic absorption, with some patients achieving very high levels and others achieving very low levels. > 4.00 © Dronabinal oral solution 4.25 mg (replicate 1) 3.50 -B Dronabino! oral solution 4.25 mg (replicate 2) te D

  11. Slide 11: Product Candidate Portfolio Summary

    Slide 11: Product Candidate Portfolio Summary

    Product Candidate Portfolio Summary Gd RespireRx Pharmaceuticals Inc | ResolutionRx | | EndeavourRx | Neuromodulators - Novel Brain Targeting Drugs AMPAkines (AMPA Receptor Positive Allosteric Modulators) = 3 Successful phase 2A trials for CX1739 and CX717 = Phase 2A ready for spinal cord injury (SC

  12. Slide 12: AMPA Glutamate Receptor Structure

    Slide 12: AMPA Glutamate Receptor Structure

    AMPA Glutamate Receptor Structure + The AMPA receptor is composed of four transmembrane proteins that form a pore, which when activated by glutamate opens and allows positive ions to enter the cell. + Ampakine binding sites are located adjacent to the glutamate binding sites and increase the normal

  13. Slide 13: CX717 Shows Significant Improvement in ADHD

    Slide 13: CX717 Shows Significant Improvement in ADHD

    CX717 Shows Significant Improvement in ADHD WR RespireRx sitet tie Inc OVERALL ADHR-RS HYPERACTIVITY INATTENTIVENESS HIGH DOSE COMPONENT (n=23) -ITT ° HIGH DOSE COMPONENT (n=23)-ITT Week 1 Week 2 Week 3 i) 4 amo Week 1 Week? Woes I Week Week Weeks 1 200 aol a | 4 + ann iL i ep} 5 Sa, 000 oo a 4200 e

  14. Slide 14: Spinal Cord Injury Metrics

    Slide 14: Spinal Cord Injury Metrics

    Spinal Cord Injury Metrics There are ~288,000 People Living with Spinal Cord Injury in the U.S.* ® 12,500 Number of new cases of Spinal Gord Injuries (SCI) each year (NSCISC) ™ $3,398,426 Lifetime Costs for Low Tetrapiegla Injury at 25 years old (Economic Impact of SCI) »><1% People who had complete

  15. Slide 15: Acute Doses of CX717 Improve Motor Neuron Firing

    Slide 15: Acute Doses of CX717 Improve Motor Neuron Firing

    Acute doses of CX717 Improve Motor Neuron Fi Animal Models of Spinal Cord Injury WN Unilateral hemi-transections at the level of the 2"¢ cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and contribute to the regulation of

  16. Slide 16: CX717 + Acute Intermittent Hypoxia Improves Motor Neuron Firing

    Slide 16: CX717 + Acute Intermittent Hypoxia Improves Motor Neuron Firing

    CX717 + Acute Intermittent Hypoxia (IH) vastly Improves Motor Neuron Firing OQ Resp pireRx Pharmaceuticals Inc Unilateral hemi-transections at the level of the 2" cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and contri

  17. Slide 17: GABA Receptor Structure

    Slide 17: GABA Receptor Structure

    GABA, Receptor Structure WN RespireRx Pharmaceuticals Inc * The GABA, receptor is composed of five GABA, receptor transmembrane proteins that form a pore, which when activated by GABA opens and allows chloride to enter the cell. * GABA Positive Allosteric Modulators (PAM) binding sites are located a

  18. Slide 18: Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care

    Slide 18: Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care

    Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care loAN) RespireRx Pharmaceuticals Inc [ Model System Species Efficacy Reference [ (CHEMICAL SEIZURE PROVOCATION MODELS [Pentylenetetrazol- clonic seizures Rat Diazepam Witkin et al, 2018 [ Pentyienetetrazol= clonic seizures | Mouse D

  19. Slide 19: Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care

    Slide 19: Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care

    Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care oN) RespireRx Pharmaceuticals Inc Model System ‘Species Efficacy Reference SEIZURE SENSITIZATION Corneal kindling Mouse | >Tpm Witkin et al, 2020 ‘Amygdala kindling-ADT Rat SDiazepam Witkin et al, 2018 “Amygdala kindling-ADD Rat Di

  20. Slide 20: Translational Results Predict Human Efficacy

    Slide 20: Translational Results Predict Human Efficacy

    Translational Results Predict Human Efficacy OQ RespireRx Pharmaceuticals Inc | KRM-II-81 Reduces Epileptiform Activity in Cortical Slices from Juvenile Epileptic Patients Picrotoxin stimulation 4-AP stimulation 015 jut } © Control * o singel iis occ: Electrical recordings were made from epileptic b

  21. Slide 21: Chronic Pain — Neuropathic and Inflammatory

    Slide 21: Chronic Pain — Neuropathic and Inflammatory

    Chronic Pain — Neuropathic and Inflammatory Resp pireRx Pharmaceuticals Inc ‘Compound | Pain model ‘Species Comparators References KRMAFSI | Acetic and lactic-acid-induced writhing, TCR mice ‘Morphine Lewter et al, 2017) nesting and locomotion KRMAFISB | Acetic and lactic-acid-induced writhing, TCR

  22. Slide 22: KRM-II-81 Is Efficacious Against Neuropathic Pain

    Slide 22: KRM-II-81 Is Efficacious Against Neuropathic Pain

    KRM-II-81 Is Efficacious Against Neuropathic Pain RespireRx Pharmaceuticals Inc Tolerance does not develop with repeated administration of KRM-II-81 A Mechanical hyperalgesia B Thermal allodynia KRM-IL-B1: green MPAII-80: blue Gabapentin: red Vehicle: black Vehicle-Vehicle: brown 0s. Effects of dail

  23. Slide 23: Intellectual Property

    Slide 23: Intellectual Property

    Intellectual Property DN RespireRx Pharmaceuticals Inc | ResolutionRx | | EndeavourRx | AMPAkines Dronabinol (A9-THC) = License to issued method-of-use patent in the US, Broad family of patents UK and Germany for the use of dronabinol for treating OSA (expires 2025 in U.S.) = Patent longevity: compo

  24. Slide 24: Global Market Opportunities

    Slide 24: Global Market Opportunities

    Global Market Opportunities DN RespireRx | ResolutionRx | Dronabinol (A9-THC) Obstructive Sleep Apnea (OSA): Potential $ multi-billion market with no approved drugs available Estimated 30 million US patients and 28 million in UK and Germany combined New superior formulation offers potential for impr

  25. Slide 25: Planned Short-Term Milestones

    Slide 25: Planned Short-Term Milestones

    Planned Short-Term Milestones GQ RespireRx Pharmaceuticals Inc ResolutionRx | EndeavourRx | Dronabinol (A9-THC) AMPAkines Initiate SCI phase 2A studies Patent filings Pre-IND meeting with FDA PK studies with new formulation GABAkines Patent filings g = Complete pre-clinical development of lead compo

  26. Slide 26: Corporate Summary

    Slide 26: Corporate Summary

    QL NN KN < Corporate Summary ow) RespireRx Pharmaceuticals Inc Highly desirable assets — advancing clinical programs and patent estate Diverse portfolio of novel products across multiple therapeutic categories and indications Broad flexibility in identifying unique investment structures Strategic pa

  27. Slide 27: RespireRx - Product Candidate Development Status

    Slide 27: RespireRx - Product Candidate Development Status

    RespireRx Pharmaceuticals Inc RespireRx - Product Candidate Development Status ; : Preclinical Phase 1 Phase 2 Phase 3 ResolutionRx - Cannabinoids Dronabinol — OSA SS Dronabinol Formulation == EndeavourRx - Neuromodulators AMPAkines CX717 - ADHD a €X1739-Spinal Cord j yl CX1942 —-follow-up compound

  28. Slide 28: RespireRx: Capital Structure and Market Metrics

    Slide 28: RespireRx: Capital Structure and Market Metrics

    spireRx: Capital Structure and Market Metrics AyRespireRx As of June 30, 2022 (unless indicated otherwise) Common Stock (rounded) 117,069,000. Common Stock Equivalents of all Convertible Notes and 186,232,000 Preferred Stock issued (as if converted), Options and Warrants Granted (rounded)* Total 303

  29. Slide 29: Separate Business Units for Different Platforms

    Slide 29: Separate Business Units for Different Platforms

    Separate Business Units for Different Platforms GQ Resp pireRx Pharmaceuticals Inc RespireRx Pharmaceuticals. Inc. (OTCQB:RSPI) *EndeavourRx *ResolutionRx Neuromodulators Pharmaceutical Cannabinoids “We are contemplating the reorganization as there are several advantages to separating these platform

  30. Slide 30: RespireRx - Organizational Structure

    Slide 30: RespireRx - Organizational Structure

    RespireRx - Organizational Structure RespireRx Pharmaceuticals Inc A. Lippa PhD 30

  31. Slide 31: Discovery Scientific Team Leaders

    Slide 31: Discovery Scientific Team Leaders

    Discovery Scientific Team Leaders WN RespireRx Pharmaceuticals Inc * Dr. Arnold Lippa, Executive Chairman and CSO at RespireRx, has spent the last 9 years clinically developing low impact ampakines for a variety of neuronal disorders. He also is a leading expert in GABA, receptors, having discovered

  32. Slide 32: (OKCQEIRSEN

    Slide 32: (OKCQEIRSEN

    RespireRx Pharmaceuticals Inc (OKCQEIRSEN COmtdcits Ueati cinsioliis, CAO) UMAaLgolis ChecpIretxecOnn Ciees4e720)

Source: SEC EDGAR · 8-K filed Nov 10, 2022

More decks from RespireRx Pharmaceuticals Inc